Lung cancer: Immunosurveillance, immunoediting or immunoepigenetics?

Lung cancer is amongst the most frequent and malignant of neoplasms. Its mortality rates place it first of all types of cancer with more than 1.000.000 deaths annually worldwide. It is characterized by a series of biological and clinical features that position it in the epicenter of current research efforts. To this end, it is noted that this cancer responds poorly to various immunotherapeutic interventions as opposed to other malignancies.

Submit your paper

Instructions to Authors

Issues

Send by email

A real-world study of PD-L1 testing patterns and PD-1/PD-L1 inhibitor therapy in patients with metastatic non-small cell lung cancer: An analysis of the Sotiria Hospital lung cancer registry

New therapies in small cell lung cancer: A narrative review

A survival analysis of cutaneous metastases in lung cancer: A 25-year experience

Quality of Life after endobronchial intervention of malignant central airway obstruction

Chemotherapy in patients with lung cancer and interstitial lung disease

Indexes

Keywords index

Topics index

Authors index

eISSN:	1791-4914
ISSN:	1105-848X

The views and opinions expressed in the published articles are strictly those of the author(s). 21 December 2021.